RESUMEN
Parkinson's disease (PD) is the second most common neurological disorder, associated with decreased dopamine levels in the brain. The goal of this study was to assess the potential of a regenerative medicine-based cell therapy approach to increase dopamine levels. In this study, we used rat adrenal pheochromocytoma (PC12) cells that can produce, store, and secrete dopamine. These cells were microencapsulated in the selectively permeable polymer membrane to protect them from immune responses. For fabrication of the microcapsules, we used a modified Buchi spray dryer B-190 that allows for fast manufacturing of microcapsules and is industrially scalable. Size optimization of the microcapsules was performed by systematically varying key parameters of the spraying device. The short- and long-term stabilities of the microcapsules were assessed. In the in vitro study, the cells were found viable for a period of 30 days. Selective permeability of the microcapsules was confirmed via dopamine release assay and micro BCA protein assay. We found that the microcapsules were permeable to the small molecules including dopamine and were impermeable to the large molecules like BSA. Thus, they can provide the protection to the encapsulated cells from the immune cells. Griess's assay confirmed the non-immunogenicity of the microcapsules. These results demonstrate the effective fabrication of microcapsules encapsulating cells using an industrially scalable device. The microcapsules were stable, and the cells were viable inside the microcapsules and were found to release dopamine. Thus, these microcapsules have the potential to serve as the alternative or complementary treatment approach for PD.
Asunto(s)
Compuestos de Aluminio/síntesis química , Cápsulas/síntesis química , Encapsulación Celular/métodos , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Enfermedad de Parkinson , Compuestos de Sodio/síntesis química , Compuestos de Aluminio/administración & dosificación , Compuestos de Aluminio/metabolismo , Animales , Encéfalo/metabolismo , Cápsulas/administración & dosificación , Cápsulas/metabolismo , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Dopamina/metabolismo , Ratones , Células PC12 , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/terapia , Polímeros/administración & dosificación , Polímeros/síntesis química , Polímeros/metabolismo , Estudios Prospectivos , Células RAW 264.7 , Ratas , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/metabolismo , Resultado del TratamientoRESUMEN
BACKGROUND: We evaluated the tolerability, pharmacokinetics (PK) and preliminary efficacy of KML001, an oral trivalent arsenical, as a monotherapy in patients with advanced solid tumors. RESEARCH DESIGN AND METHODS: With a standard 3 + 3 design for dose-escalation stage, the planned dose levels of KML001 were 5, 7.5, 10, 12.5, and 15 mg/day for 28 days. Once the maximum tolerated dose was determined, 22 subjects were additionally enrolled for dose-expansion stage. PK analysis was performed in the 5, 10, and 15 mg/day cohort at the dose-escalation stage and also at the dose-expansion stage. Moreover, response was assessed using the standard RECIST 1.1. RESULTS: A total of 45 Korean subjects were enrolled. No DLT was reported at the dose-escalation stage. Three DLTs, two cases of prolonged QTc interval and one of neutropenia, were reported in the 12.5 mg/day cohort at the dose-expansion stage. Higher total daily doses up to 12.5 mg/day of KML001 resulted in higher trough plasma concentrations. Among the 18 subjects who completed 2 cycles of therapy, 15 had progressive disease and 3 had stable disease. CONCLUSIONS: Doses equal to or greater than 10 mg/day KML001 alone were tolerable and produced plasma concentrations higher than biologically relevant targets.
Asunto(s)
Antineoplásicos/administración & dosificación , Arsenitos/administración & dosificación , Neoplasias/tratamiento farmacológico , Compuestos de Sodio/administración & dosificación , Adulto , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/farmacocinética , Arsenitos/efectos adversos , Arsenitos/farmacocinética , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Dosis Máxima Tolerada , Persona de Mediana Edad , Neoplasias/patología , Compuestos de Sodio/efectos adversos , Compuestos de Sodio/farmacocinética , Resultado del TratamientoRESUMEN
AIMS: Arsenic has carcinogenic properties because of the formation of Reactive Oxygen Species (ROS). ROS damages different macromolecules, tissues and organs, and severely exhausts cellular antioxidants. BACKGROUND: Cytosolic and mitochondrial contribution of ROS production by arsenic are not well reported. In regard to the issues of therapy against arsenic or any other toxicity, natural product has gained its popularity due to its less side-effects and non-invasive nature. OBJECTIVES: Here, as an ethnomedicine, the flesh-extract (BBE; 100mg/100g bw) of Bellamya bengalensis (an aquatic mollusk) was applied in arsenic intoxicated (0.6 ppm/100g bw/for 28 days alone or in combination with BBE) experimental rats. Our objective was to study the anti-oxidative and anti-apoptotic role of BBE in hepato-gastrointestinal tissue damage by arsenic. METHODS: DNA fragmentation assay, catalase activity (gel-zymogram assay) suggests that BBE has a strong protective role against arsenic toxicity, which is decisively demonstrated in hepatic histoarchitecture study by HE (hematoxylin and eosin) staining and by intestinal PAS (Periodic Acid Schiff) staining. RESULTS: Measurement of mitochondrial-membrane-potential by fluorescent microcopy clearly demonstrated less membrane damage and lower release of the redox-active inner-membrane product (cytochrome-C, ubiquinone, etc.) in BBE supplemented group compared to that of the only arsenic fed group. The present study clearly suggests that mitochondrial disintegrity is one of the major causes of ROS mediated tissue damage by arsenic. CONCLUSION: This study also offers an option for prevention/treatment against arsenic toxicity and its carcinogenicity by widely available low-cost, non-invasive Bellamya extract by protecting cytoskeleton, DNA and mitochondria in the cell.
Asunto(s)
ADN/efectos de los fármacos , Intestinos/efectos de los fármacos , Hígado/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Sustancias Protectoras/farmacología , Administración Oral , Animales , Arsenitos/administración & dosificación , Relación Dosis-Respuesta a Droga , Agua Dulce , Intestinos/patología , Hígado/patología , Masculino , Medicina Tradicional , Estructura Molecular , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/química , Sustancias Protectoras/aislamiento & purificación , Ratas , Caracoles , Compuestos de Sodio/administración & dosificación , Relación Estructura-ActividadRESUMEN
Arsenic (As), a potent environmental toxin, causes cardiac functional impairments. Ferulic acid (FA), a ubiquitous dietary hydroxycinnamate, exerts beneficial effects on human health. Hence, the present study investigated the effect of FA on myocardial oxidative stress parameters, ATP level, the status of cardiac cytoskeleton intermediate filaments-desmin and vimentin, and AMPK signaling proteins in As-intoxicated rats. Wistar rats were administered orally with FA-40 mg/kg and As-5 mg/kg alone and in combination for 30 days. Myocardial As content, serum cardiac marker enzyme activities including creatine kinase-isoenzyme, lactate dehydrogenase, and aspartate aminotransferase were increased in As-exposed rats. An accumulation of myocardial oxidants such as reactive oxygen species, lipid peroxidation, nitric oxide, protein carbonyl content, and histological aberrations was observed. A significant decrease of myocardial antioxidants comprises superoxide dismutase, catalase, glutathione peroxidase, reduced glutathione, and ascorbic acid and declined expression of desmin and vimentin was noted. Impaired energy signaling molecules AMPKα (Thr172), AMPKß1/2 (Ser108), ACC (Ser79), and intracellular myocardial ATP depletion were observed in As-intoxicated animals. FA attenuates As-induced cardiac dysfunction by restoring the expression of intermediate filaments and AMPK proteins. Based on the above findings, FA treatment could be used as a novel therapeutic against As-induced cardiac dysfunction.
Asunto(s)
Arsenitos/antagonistas & inhibidores , Ácidos Cumáricos/farmacología , Miocardio/metabolismo , Compuestos de Sodio/antagonistas & inhibidores , Administración Oral , Animales , Arsenitos/administración & dosificación , Arsenitos/toxicidad , Ácidos Cumáricos/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Ratas , Ratas Wistar , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/toxicidadRESUMEN
Arsenic is a common toxic contaminant in food and drinking water. Metabolic activation of arsenic species produces reactive trivalent intermediates that can disrupt cellular regulatory systems by covalent binding to thiol groups. Arsenic exposures have been associated with human diseases including cancer, diabetes, lung and cardiovascular disorders and there is accumulating evidence that early life exposures are important in the etiology. Previous toxicokinetic studies of arsenite ingestion in neonatal CD-1 mice showed consistent evidence for metabolic and physiologic immaturity that led to elevated internal exposures to trivalent arsenic species in the youngest mice, relative to adults. The current study in rhesus monkeys showed that metabolism and binding of trivalent intermediates after arsenite ingestion were similar between adult monkeys and CD-1 mice. Unlike neonatal mice, monkeys from the age of 5-70 days showed similar metabolism and binding profiles, which were also similar to those in adults. The absence of evidence for metabolic immaturity in monkeys suggests that toxicological effects observed in mice from early postnatal exposures to arsenic could over-predict those possible in primates, based on significantly higher internal exposures.
Asunto(s)
Arsenitos/farmacocinética , Compuestos de Sodio/farmacocinética , Contaminantes Químicos del Agua/farmacocinética , Administración Oral , Factores de Edad , Animales , Animales Recién Nacidos/metabolismo , Arsenitos/administración & dosificación , Arsenitos/metabolismo , Eritrocitos/metabolismo , Femenino , Macaca mulatta/metabolismo , Masculino , Ratones , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/metabolismo , Contaminantes Químicos del Agua/administración & dosificación , Contaminantes Químicos del Agua/metabolismoRESUMEN
BACKGROUND: Sodium meta-arsenite (NaAsO2, KML001) is a potential oral anticancer agent acting on telomerase and telomere length. This prospective study evaluated its safety, tolerability, and effectiveness as salvage chemotherapy in patients with advanced biliary tract cancer (BTC) resistant to gemcitabine-based chemotherapy. METHODS: Forty-four patients (21 women and 23 men) with advanced BTC and failure history of gemcitabine-based chemotherapy, performance status (PS) 0-2, normal cardiac, hepatic, and renal function were enrolled. Daily dose of KML001 (7.5â¯mg. p.o.) was administered to eligible subjects for 24 weeks divided into six treatment cycles. Response was evaluated bimonthly using CT. RESULTS: After an average of 1.5 months of treatment (range: 0.5-10.0), 3 patients (6.8%) obtained progression-free status, 23 patients (52.3%) had disease progression, and 18 patients (40.9%) dropped out before evaluation. One patient (2.3%) completed six treatment cycles without progression. During the treatment, morphine dosage kept the same or decreased in 20 patients (47.6%). Nine patients (20.5%) experienced grade-3 adverse events (AEs), while no patient experienced grade-4 AEs. The most common AEs were liver enzyme elevation (11/44, 25%) and anemia (10/44, 22.7%). KML001 was discontinued in six patients (13.6%) due to AEs, including liver toxicity (nâ¯=â¯3), QTc prolongation (nâ¯=â¯2), and abdominal pain (nâ¯=â¯1). CONCLUSIONS: KML001 did not have enough anticancer effect on patients with advanced BTC resistant to gemcitabine. However, KML001 was safe and well-tolerable in terms of AEs and pain control when used as salvage therapy. Further studies are needed to establish arsenic agents as a reliable treatment option in patients with BTC.
Asunto(s)
Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Arsenitos/administración & dosificación , Neoplasias del Sistema Biliar/tratamiento farmacológico , Terapia Recuperativa , Compuestos de Sodio/administración & dosificación , Administración Oral , Anciano , Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Arsenitos/efectos adversos , Neoplasias del Sistema Biliar/diagnóstico por imagen , Neoplasias del Sistema Biliar/mortalidad , Neoplasias del Sistema Biliar/patología , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Esquema de Medicación , Resistencia a Antineoplásicos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Supervivencia sin Progresión , Estudios Prospectivos , Compuestos de Sodio/efectos adversos , Factores de Tiempo , Tomografía Computarizada por Rayos X , GemcitabinaRESUMEN
Arsenic is carcinogenic to human beings, and environmental exposure to arsenic is a public health issue that affects large populations around the world. Thus, studies are needed to determine the mode of action of arsenic and to prevent harmful effects that arise from arsenic intake. In particular, knowledge of the effects of arsenic exposure in individuals who are undergoing a carcinogenesis process is lacking. The present study was performed in mice to evaluate the effect of chronic As3+ administration on peritoneal and alveolar macrophages; the As3+ was administered in drinking water over 9 months and there was a two-stage carcinogenesis process. At the end of the experiment, the number of tumors stabilized to below the control values, but the tumors showed increased malignancy. Our objective was to evaluate the systemic effects of chronic As3+ingestion in a population of macrophages that was derived from the peritoneal cavity and the broncho-alveolar trunk of cancerized mice since they are the first line of defense in the immune system. The results showed that the macrophages under all conditions retained their ability to self-regulate their metabolic reactivity. This feature was more evident in peritoneal macrophages than in alveolar macrophages. Furthermore, an increase in the number of macrophages from animals receiving higher doses of As3+ compared to untreated animals was observed. These findings indicate that certain parameters associated with two-stage skin carcinogenesis are modified by the presence of As3+ in drinking water.
Asunto(s)
Arsenitos/toxicidad , Carcinogénesis/inducido químicamente , Carcinógenos/toxicidad , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Compuestos de Sodio/toxicidad , Animales , Arsenitos/administración & dosificación , Carcinogénesis/metabolismo , Carcinogénesis/patología , Carcinógenos/administración & dosificación , Células Cultivadas , Ingestión de Líquidos , Femenino , Macrófagos/patología , Ratones , Compuestos de Sodio/administración & dosificaciónRESUMEN
Inorganic arsenic (iAs) is an important natural pollutant. Millions of individuals worldwide drink water with high levels of iAs. Arsenic exposure has been associated to cognitive deficits. However, the underlying mechanisms remain unknown. In the present work we investigated in female adult offspring the effect of the exposure to low arsenite sodium levels through drinking water during pregnancy and lactation on short- and long-term memory. We also considered a possible underlying neurotoxic mechanism. Pregnant rats were exposed during pregnancy and lactation to environmentally relevant iAs concentrations (0.05 and 0.10â¯mg/L). In 90-day-old female offspring, short-term memory (STM) and long-term memory (LTM) were evaluated using a step-down inhibitory avoidance task. In addition, we evaluated the α7 nicotinic receptor (α7-nAChR) expression, the transaminases and the oxidative stress levels in hippocampus. The results showed that the exposure to 0.10â¯mg/L iAs in this critical period produced a significant impairment in the LTM retention. This behavioral alteration might be associated with several events that occur in the hippocampus: decrease in α7-nAChR expression, an increase of glutamate levels that may produce excitotoxicity, and a decrease in the antioxidant enzyme catalase (CAT) activity.
Asunto(s)
Arsenitos/toxicidad , Ácido Glutámico , Lactancia/efectos de los fármacos , Trastornos de la Memoria/inducido químicamente , Estrés Oxidativo/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Compuestos de Sodio/toxicidad , Receptor Nicotínico de Acetilcolina alfa 7/biosíntesis , Animales , Arsenitos/administración & dosificación , Femenino , Ácido Glutámico/metabolismo , Lactancia/metabolismo , Trastornos de la Memoria/metabolismo , Estrés Oxidativo/fisiología , Embarazo , Efectos Tardíos de la Exposición Prenatal/metabolismo , Ratas , Ratas Wistar , Compuestos de Sodio/administración & dosificaciónRESUMEN
The present study reports beneficial effect of hydroxytyrosol (HT) against arsenic (As)-induced oxidative stress in the rat brain. Rats were orally administered with sodium arsenite dissolved in distilled water (25 ppm, by oral gavage) for 8 weeks or HT (10 mg/kg b. wt.) in combination with As. Results showed increase in protein oxidation and lipid peroxidation, while catalase and superoxide dismutase (SOD) activities as well as GSH content were decreased after As exposure in rat brain. Fourier transform infrared analysis showed significant alteration in peak area values that also validated the oxidative damage to lipids and proteins. In addition, As exposure caused increase in protein expression of caspase-3 and Bax, while Bcl-2 expression was downregulated resulting in translocation of cytochrome c from mitochondria to cytosol. Treatment of HT with As reversed protein oxidation, lipid peroxidation, and increased GSH content as well as catalase and SOD activities. Administration of HT also prevented translocation of cytochrome c from mitochondria and increased mitochondria/cytosol ratio of cytochrome c. Hence, treatment of HT with As improved antioxidant system and efficiently lowered the generation of oxidative stress in rat brain.
Asunto(s)
Arsenitos/toxicidad , Encéfalo/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Alcohol Feniletílico/análogos & derivados , Compuestos de Sodio/toxicidad , Administración Oral , Animales , Antioxidantes/metabolismo , Arsenitos/administración & dosificación , Western Blotting , Encéfalo/enzimología , Encéfalo/metabolismo , Caspasa 3/metabolismo , Catalasa/metabolismo , Citocromos c/metabolismo , Citosol/metabolismo , Regulación hacia Abajo , Glutatión/metabolismo , Metabolismo de los Lípidos , Peroxidación de Lípido/efectos de los fármacos , Masculino , Mitocondrias/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Alcohol Feniletílico/farmacología , Transporte de Proteínas , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas Wistar , Compuestos de Sodio/administración & dosificación , Espectroscopía Infrarroja por Transformada de Fourier , Superóxido Dismutasa/metabolismoRESUMEN
Long-term consumption of sodium arsenite contaminated water can cause endemic arsenic disease. The proteome profile changes of liver fibrosis after exposure to arsenite containing water remain unclear. In this study, Sprague-Dawley (SD) male rats were treated with sodium arsenite (iAs3+), using a daily dose of 1.36 mg/kg body weight (medium dose group, M), 2.73 mg/kg body weight (high dose group, H) or deionized water (control group, C). Isobaric tags for relative and absolute quantitation (iTRAQ) were used to identify the different abundant proteins (DAPs) after arsenic-induced liver fibrosis. A total of 2987 high-quality proteins were detected (95% confident peptides ≥ 2), 608 of which were differentially expressed (fold change > 2 and p < 0.05) in M group and 475 in H group. Moreover, 431 DAPs were found in both M and H groups and used in subsequent bioinformatic analyses. Gene ontology (GO) analysis revealed 4,709 GO terms could be mapped, among which purine binding, actin filament binding and protein kinase binding were the most enriched terms for molecular function category. In addition, protein-protein interaction analysis showed six clusters of interaction networks. Our data provided new insights into the proteome changes after arsenic-induced liver fibrosis in model rats.
Asunto(s)
Arsénico/toxicidad , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/patología , Redes y Vías Metabólicas , Proteoma/análisis , Animales , Arsenitos/administración & dosificación , Modelos Animales de Enfermedad , Ontología de Genes , Proteómica/métodos , Ratas Sprague-Dawley , Compuestos de Sodio/administración & dosificación , Contaminantes Químicos del Agua/toxicidadRESUMEN
To further characterize the mechanisms underlying liver toxicity induced by arsenic, we examined in this study the effect of arsenic on thioredoxin (Trx) and the apoptotic signaling pathways in human liver HHL-5 cells. The cells were treated with 0, 2, 5, and 10 µM of sodium arsenite for 24 h, and the changes of Trx1 and thioredoxin reductase (TrxR1) as well as intracellular ROS and apoptosis were examined. A concentration-dependent increase in mRNA and protein levels of Trx1 and TrxR1 was observed in arsenic-treated cells. Intracellular ROS levels and apoptosis were also significantly increased in a concentration-dependent manner. In line with this, protein levels of Bax and cytochrome C were increased and Bcl-2 was decreased by arsenic treatments. Increases in caspase 3 activity were observed. These results indicate that Trx is involved in arsenic-induced liver cell injury, probably through the apoptotic signaling pathway. However, further studies are needed to elucidate on these findings.
Asunto(s)
Apoptosis/efectos de los fármacos , Intoxicación por Arsénico/metabolismo , Intoxicación por Arsénico/patología , Arsenitos/farmacología , Hígado/efectos de los fármacos , Hígado/patología , Compuestos de Sodio/farmacología , Tiorredoxinas/metabolismo , Arsenitos/administración & dosificación , Células Cultivadas , Relación Dosis-Respuesta a Droga , Humanos , Hígado/metabolismo , Compuestos de Sodio/administración & dosificación , Relación Estructura-ActividadRESUMEN
PURPOSE: Alkali metal ablation is newly emerging as an effective, economic and minimally invasive ablation therapy. This study is dedicated to demonstrate the high efficiency of NaK alloy ablation on in vivo tumors with different stages in mice. MATERIAL AND METHODS: Panc02 tumor cells were injected into 21 female C57B/L mice, which were divided into three groups. Two experimental groups of mice received the same percutaneous NaK alloy injection for a week apart. The inner temperature response and surface temperature distribution were measured using a thermal couple and an infrared camera. After each ablation experiment, two mice in each group were chosen randomly to make pathological sections. The tumor volumes were measured once every two days. At the end, all tumors were cut off to calculate the tumor inhibition rates. RESULTS: The NaK alloy-induced ablation therapy produced an obvious temperature increase (85 °C) in the ablation region and the high temperature distribution was relatively concentrated. The histopathology sections showed that developing stage tumors received incomplete destruction of the malignant cells compared with early stage tumors. The tumor inhibition rate in the early and developing tumor treatment groups were 88.5% and 67.6%, respectively. CONCLUSIONS: This technology provides a nearly thorough ablation treatment for early stage tumors and also a palliative treatment for developing tumors.
Asunto(s)
Técnicas de Ablación/métodos , Aleaciones/administración & dosificación , Hipertermia Inducida/métodos , Metales Alcalinos/administración & dosificación , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/terapia , Aleaciones/farmacología , Animales , Temperatura Corporal , Línea Celular Tumoral , Modelos Animales de Enfermedad , Femenino , Metales Alcalinos/farmacología , Ratones , Ratones Endogámicos C57BL , Neoplasias Experimentales , Compuestos de Potasio/administración & dosificación , Compuestos de Potasio/farmacología , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/farmacología , Carga TumoralRESUMEN
Sodium arsenite (NaAsO2) is one of the major environmental toxicants with severe toxicological consequences in some developing and developed countries. Rats in Group A received normal saline. Genotoxicity and apoptosis were induced by single intraperitoneal injection of 10 mg/kg sodium arsenite to rats in Groups B-F. Rats in Groups C and D had earlier been pretreated with Azadirachta indica (100 and 200 mg/kg) or E and F with vitamin E (50 and 100 mg/kg), respectively. Markers of oxidative stress, inflammation, hepatic damage, genotoxicity, and apoptosis were assessed. Pretreatment of rats with either Azadirachta indica or vitamin E led to a significant (p <.05) increase in the activities of glutathione-S-transferase (GST), catalase (CAT), superoxide dismutase (SOD), and reduced glutathione (GSH) in the liver compared to the group that received NaAsO2 alone. Markers of oxidative stress and inflammation, malondialdehyde (MDA), hydrogen peroxide (H2O2) generation, nitric oxide (NO), and myeloperoxidase (MPO), were significantly (p <.05) lowered in rats pretreated with Azadirachta indica or vitamin E. The frequency of micronucleated polychromatic erythrocytes (MNPCEs) and expression of caspase-3 were significantly (p <.05) reduced in rats pretreated with either Azadirachta indica or vitamin E compared to rats intoxicated with arsenite. Histopathology of the liver showed areas of infiltration of inflammatory cells with deaths of numerous hepatocytes in NaAsO2-intoxicated rats, and these were reversed by Azadirachta indica. Together, we report for the first time the genoprotective and antiapoptotic effect of Azadirachta indica by a significant reduction in the frequency of micronuclei-induced apoptosis and oxidative stress by arsenic intoxication.
Asunto(s)
Apoptosis/efectos de los fármacos , Intoxicación por Arsénico/prevención & control , Azadirachta/química , Suplementos Dietéticos , Extractos Vegetales/uso terapéutico , Sustancias Protectoras/uso terapéutico , Vitamina E/uso terapéutico , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/uso terapéutico , Antioxidantes/administración & dosificación , Antioxidantes/uso terapéutico , Intoxicación por Arsénico/inmunología , Intoxicación por Arsénico/metabolismo , Intoxicación por Arsénico/patología , Arsenitos/administración & dosificación , Arsenitos/antagonistas & inhibidores , Arsenitos/toxicidad , Biomarcadores/sangre , Biomarcadores/metabolismo , Inyecciones Intraperitoneales , Hígado/efectos de los fármacos , Hígado/inmunología , Hígado/metabolismo , Hígado/patología , Masculino , Micronúcleos con Defecto Cromosómico/inducido químicamente , Infiltración Neutrófila/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Sustancias Protectoras/administración & dosificación , Distribución Aleatoria , Ratas , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/antagonistas & inhibidores , Compuestos de Sodio/toxicidad , Vitamina E/administración & dosificaciónRESUMEN
Arsenic (As) is ubiquitous in the earth's crust, with typical dietary intake in developed countries <1 µg/kg bw/d, and atypical groundwater exposures in developing countries approaching 50 µg/kg bw/d. Arsenic exposures are linked with human diseases and doses of toxicological concern are similar to typical dietary intake estimates. The methylation of arsenite by arsenite-3-methyltransferase (As3MT) promotes the clearance of arsenic as pentavalent species, but also generates reactive trivalent intermediates. This study measured inorganic arsenic and its metabolites in pentavalent and trivalent states in blood, tissues, and excreta after oral administration of arsenite (50-200 µg/kg bw). While liver was a major site for clearance of arsenite and formation of methylated species, it also had extensive binding of trivalent intermediates; however, thiol exchange and oxidation reactions of trivalent arsenic were facile since dimethylarsinic acid (DMAV) was the predominant species in blood and urine. Consistent evidence was observed for a non-linear relationship between doses above 50 µg/kg bw and levels of bound trivalent As metabolites. The abundance of protein-bound trivalent arsenic within target tissues should correlate with disruption of critical cellular processes, which rely on defined interactions of thiol functional groups, and could provide dose-response relationships from animal models for human risk assessment.
Asunto(s)
Arsenitos/química , Arsenitos/farmacocinética , Compuestos de Sodio/química , Compuestos de Sodio/farmacocinética , Animales , Arsenitos/administración & dosificación , Arsenitos/toxicidad , Análisis Químico de la Sangre , Relación Dosis-Respuesta a Droga , Heces/química , Femenino , Riñón/efectos de los fármacos , Riñón/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Metilación , Ratones , Estructura Molecular , Oxidación-Reducción , Proyectos Piloto , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/toxicidad , Orina/químicaRESUMEN
Timely recanalization of infarct related artery along with effective myocardial cell reperfusion represents a major challenge in the management of STEMI. The reperfusion of coronary arteries can induce further cardiomyocyte death by generating oxidative stress, which itself can mediate myocardial damage through a number of different mechanisms. Based on experimental and clinical studies, interventions to treat reperfusion injury by antioxidants were considered to be an appropriate therapeutic option. We emphasize the hypothesis that glutathione sodium salt, a physiologic antioxidant, may be of value when administered to STEMI patients both at an early stage of myocardial reperfusion by primary angioplasty and for up to three days after the procedure, in addition to standard treatment.
Asunto(s)
Glutatión/administración & dosificación , Glutatión/metabolismo , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/metabolismo , Daño por Reperfusión Miocárdica/metabolismo , Daño por Reperfusión Miocárdica/prevención & control , Compuestos de Sodio/administración & dosificación , Animales , Quimioterapia Adyuvante/métodos , Medicina Basada en la Evidencia , Humanos , Modelos Cardiovasculares , Sales (Química)/administración & dosificación , Resultado del TratamientoRESUMEN
Cardiovascular disease and diabetes mellitus are prominent features of glucose and lipid metabolism disorders. Adiponectin is a key adipokine that is largely involved in glucose and lipid metabolism processes. A growing body of evidence suggests that chronic exposure to inorganic arsenic is associated with cardiovascular disease and diabetes mellitus. We hypothesized that arsenic exposure may increase the risk of cardiovascular disease and diabetes mellitus by affecting the level of adiponectin. In this study, we examined serum adiponectin levels, as well as serum levels of metabolic measures (including fasting blood glucose, insulin, total cholesterol, triglyceride, and high-density lipoprotein (HDL)-cholesterol) in C57BL/6 mice exposed to inorganic arsenic in drinking water (5 and 50 ppm NaAsO2) for 18 weeks. Body mass and adiposity were monitored throughout the study. We found no significant changes in serum insulin and glucose levels in mice treated with arsenic for 18 weeks. However, arsenic exposure decreased serum levels of adiponectin, triglyceride, and HDL-cholesterol. Further, an inverse relationship was observed between urinary concentrations of total arsenic and serum levels of adiponectin. This study suggests that arsenic exposure could disturb the metabolism of lipids and increase the risk of cardiovascular disease by reducing the level of adiponectin.
Asunto(s)
Adiponectina/sangre , Arsenitos/administración & dosificación , Arsenitos/toxicidad , Agua Potable/administración & dosificación , Agua Potable/química , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/toxicidad , Animales , Arsenitos/orina , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/inducido químicamente , Lípidos/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Compuestos de Sodio/orinaRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Chronic arsenic poisoning due to contaminated subsoil water is a threat to society in West Bengal, India and in Bangladesh. The human being may also be affected by the exposed cattle from the affected area by consuming milk, egg, meat and others. In Ayurveda, several herbs like Haridra (turmeric), Shunthi (dried ginger root) and others are used for the management of arsenic poisoning. AIM OF THE STUDY: The study was conducted to find out the ameliorative effect of turmeric and ginger powder against experimentally induced arsenic toxicity in calves. MATERIALS AND METHODS: Twenty four calves were divided into four groups (group I, II, III and IV) having six animals in each group. Animals of group I, II and III were orally administered with sodium arsenite at 1mg/kg body weight for 90 days and in addition group II and group III animals were treated orally with turmeric and ginger powder respectively at 10mg/kg body weight from 46th day onwards. Group IV animals were given food and water without drug and served as control. Arsenic content was estimated in faeces, hair, urine and plasma in every 15 days. Bio-chemical, haematological and anti-oxidant parameters were also assessed. RESULTS: Turmeric and ginger powder significantly (P<0.05) reduced the plasma and hair arsenic levels through increased excretion via faeces and urine. Haemoglobin level, TEC and TLC were decreased in groups I, II and III, however these were improved significantly (P<0.05) from 75th day onwards in turmeric and ginger treated groups. Increased activity of AST and ALT were significantly decreased (P<0.05) from 75th day onwards in group II and III. Blood urea nitrogen and plasma creatinine were also significantly decreased (P<0.05) in group II and III than group I from 60th day onwards. The SOD and catalase activity were significantly (P<0.05) reduced in groups I, II and III, but these were restored at the end of the experiment in turmeric and ginger treated groups. CONCLUSION: The test drugs are found significantly effective not only to eliminate arsenic from the body but also give protection from possible damage caused by arsenic exposure, it may be concluded from the present study that turmeric and ginger can be helpful in the therapy of chronic arsenic toxicity in calves.
Asunto(s)
Intoxicación por Arsénico/tratamiento farmacológico , Arsénico/toxicidad , Extractos Vegetales/farmacología , Animales , Antioxidantes/metabolismo , Intoxicación por Arsénico/sangre , Intoxicación por Arsénico/metabolismo , Intoxicación por Arsénico/orina , Arsenitos/administración & dosificación , Bangladesh , Bovinos , Curcuma/química , Heces/química , Zingiber officinale/química , Cabello/química , India , Masculino , Medicina Ayurvédica , Leche/química , Plantas Medicinales/química , Plasma/química , Compuestos de Sodio/administración & dosificación , Orina/químicaRESUMEN
Arsenic is a groundwater pollutant and can cause various cardiovascular disorders in the exposed population. The aim of the present study was to assess whether subchronic arsenic exposure through drinking water can induce vascular dysfunction associated with alteration in plasma electrolytes and lipid profile. Rats were exposed to arsenic as 25, 50, and 100 ppm of sodium arsenite through drinking water for 90 consecutive days. On the 91st day, rats were sacrificed and blood was collected. Lipid profile and the levels of electrolytes (sodium, potassium, and chloride) were assessed in plasma. Arsenic reduced high-density lipoprotein cholesterol (HDL-C) and HDL-C/LDL-C ratio, but increased the levels of triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and electrolytes. The results suggest that the arsenic-mediated dyslipidemia and electrolyte retention could be important mechanisms in the arsenic-induced vascular disorder.
Asunto(s)
Arsenitos/farmacología , Cloruros/sangre , Agua Potable/química , Electrólitos/sangre , Lípidos/sangre , Potasio/sangre , Compuestos de Sodio/farmacología , Sodio/sangre , Animales , Arsenitos/administración & dosificación , Arsenitos/análisis , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Masculino , Ratas , Ratas Wistar , Compuestos de Sodio/administración & dosificación , Compuestos de Sodio/análisisRESUMEN
Arsenic (As) toxicity has caused an environmental tragedy affecting millions of people in the world. Little is known about the toxic effects of As on neurobehavioral and biochemical changes in vivo. Along this line of metal toxicity, co-exposure of lead (Pb) could aggravate the situation in the host. The present study was designed to explore the combined effects of As and Pb on behavioral changes like anxiety, spatial memory and learning impairment, and blood indices related to organ dysfunction. Exposure of mice to As (10 mg/kg body weight), Pb (10 mg/kg body weight), and As + Pb via drinking water significantly decreased the time spent exploring the open arms while it increased the time spent in the closed arms compared to control mice in the elevated plus maze. The mean latency time of the control group to find the platform decreased significantly during the learning for 7 days compared to all three treated groups in the Morris water maze test, and the As-exposed group spent significantly less time in the desired quadrant as compared to the control group in the probe trial. Both metals posed an anxiety-like behavior and deficits in spatial memory and learning, and also altered blood indices related to liver and kidney dysfunction, and a combined exposure of these metals inhibited the individual accumulation of As and Pb. Taken together, these data suggest that As has more toxic effects on neurobehavioral and biochemical changes than Pb, and there may be antagonism in the effects and accumulation between these two toxicants.
Asunto(s)
Arsenitos/sangre , Arsenitos/toxicidad , Conducta Animal/efectos de los fármacos , Riñón/efectos de los fármacos , Hígado/efectos de los fármacos , Compuestos Organometálicos/sangre , Compuestos Organometálicos/toxicidad , Compuestos de Sodio/sangre , Compuestos de Sodio/toxicidad , Administración Oral , Animales , Arsenitos/administración & dosificación , Biomarcadores/análisis , Biomarcadores/sangre , Biomarcadores/metabolismo , Riñón/fisiopatología , Hígado/fisiopatología , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Memoria/efectos de los fármacos , Ratones , Compuestos Organometálicos/administración & dosificación , Compuestos de Sodio/administración & dosificaciónRESUMEN
Environmental exposure to arsenic represents a serious challenge to humans and other animals. The aim of the present study was to test the protective effect of antioxidant N-acetylcysteine (NAC) either individually or in combination with a chelating agent, meso-2,3-dimercaptosuccinic acid (DMSA), against sodium arsenite oral toxicity in male rats. Five groups were used: control; arsenic group (orally administrated in a concentration of 2 mg/kg body weight [b.w.]); the other three groups were orally administrated sodium arsenite in a concentration of 2 mg/kg b.w. followed by either NAC (10 mg/kg b.w., intraperitoneally [i.p.]), DMSA (50 mg/kg b.w., i.p.) or NAC plus DMSA. Arsenic toxicity caused significant rise in serum aspartate aminotransferase, alanine aminotransferase and total bilirubin, and a significant decrease in total protein (TP) and albumin levels after 3 weeks of experimental period. In addition, arsenic-treated rats showed significantly higher arsenic content in liver and significant rise in hepatic malondialdehyde level. By contrast, sharp decreases in glutathione content and catalase and glutathione reductase activities were discernible. NAC and/or DMSA counteracted most of these physiologic and biochemical defects. NAC monotherapy was more effective than DMSA in increasing TP, while DMSA was more effective in decreasing alanine aminotransferase. The combined treatment was superior over monotherapies in recovery of TP and glutathione. Biochemical data were well supported by histopathological and ultrastructural findings. In conclusion, the combination therapy of NAC and DMSA may be an ideal choice against oxidative insult induced by arsenic poisoning.